Higher levels of SLFN11 have been linked to increased sensitivity to DNA-damaging chemotherapies, including PARP inhibitors, leading to improved PFS and OS in triple-negative breast cancer (37). The gene discussed is PARP1; the disease is triple-negative breast carcinoma.